Clinical Trial

To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM

Study acronym: ENSEMBLE
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are: * major adverse cardiovascular events within 48 months of the trial duration * microvascular events within 48 months of the trial duration
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-27; most recent amendment 2024-08-25.
Status change: Not Yet Recruiting → Recruiting 2024-08-25
Trial Details
NCT Number NCT06293417
Lead Sponsor Korea University Anam Hospital
Conditions T2DM (Type 2 Diabetes Mellitus), Dyslipidemias
Enrollment 3,958 participants
Start Date 2024-03-01
Primary Completion 2027-02-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-27